{"url_path":"/sec/vygr/8-k/2026-06-01/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1640266/0001104659-26-068591-index.html","accession_number":"0001104659-26-068591","cik":"0001640266","ticker":"VYGR","issuer_name":"Voyager Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1640266/0001104659-26-068591-index.html","primary_entity_key":"0001640266","primary_entity_name":"Voyager Therapeutics, Inc."},"word_count":738,"has_tables":true,"body_markdown":"**Item 8.01**\n\n**Other Events.**\n\n****\n\n \n\nOn June 1, 2026, Voyager Therapeutics, Inc. (the “Company”)\nannounced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for VY1706, the Company’s\ninvestigational tau silencing gene therapy developed to target intracellular and extracellular tau for Alzheimer’s disease (“AD”).\nThe Company plans to initiate a multi-site, open-label, dose-escalation clinical trial of VY1706, which is expected to begin dosing in\nthe second half of 2026.\n\n \n\nIn the clinical trial, VY1706 will be administered as a one-time, intravenous\ndose to adult participants with early AD who have evidence of tau pathology in the brain as confirmed by positron emission tomography\n(“PET”) imaging. The study is expected to enroll up to an aggregate of 18 patients across three cohorts, with the highest\ndose not exceeding 5 x 1013 vector genomes per kilogram, the highest dose tested in non-human primates in the good laboratory\npractice toxicology study. The primary endpoint of the study is to evaluate the safety and tolerability of VY1706. Secondary endpoints\nare designed to assess VY1706’s effect on tau biology, including changes in cerebrospinal fluid biomarkers of tau, as well as changes\nin tau pathology measured by tau PET imaging.\n\n \n\n**Cautionary Note Regarding Forward-Looking Statements**\n\n \n\nThis Current Report on Form 8-K contains forward-looking statements\nwithin the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including, without limitation,\nimplied and express statements about the Company’s beliefs and expectations regarding the Company’s timing and achievement\nof clinical development milestones for VY1706, including the Company’s intention to initiate clinical trials, clinical trial enrollment,\nand achievement of first-in-human dosing in AD in the second half of 2026. The use of words such as “may,” “will,”\n“might,” “would,” “could,” “should,” “expect,” “plan,” “anticipate,”\n“believe,” “potential,” “intend,” “seek,” “predict,” “estimate,”\n“project,” “target,” or “continue” and other similar expressions are intended to identify forward-looking\nstatements, although not all forward-looking statements contain these identifying words.\n\n \n\nAll forward-looking statements are based on management’s current\nestimates and assumptions and are subject to a number of risks, uncertainties, and important factors that may cause actual results to\ndiffer materially from any forward-looking statements in this Form 8-K. Factors include, among others, the risks and uncertainties\ninherent in the development of product candidates, including the initiation, enrollment, timing, cost, progress, and results of the Company’s\nplanned and future clinical trials; expectations and decisions of regulatory authorities; the Company’s ability to replicate positive\nresults from earlier preclinical studies or clinical trials in current or future clinical trials; potential adverse events the Company\nmay encounter that could negatively impact development; outcomes of third-party preclinical studies and clinical trials that could impact\nthe Company’s development plans; the Company’s ability to demonstrate that current or future product candidates are safe and\neffective for their proposed indications; the Company’s scientific approach and continued development of its technology platforms,\nincluding the TRACER and non-viral discovery platforms; the development by third parties of capsid or non-viral identification platforms\nthat may be competitive to its platforms and programs; the Company’s ability to create and protect its intellectual property rights;\nthe progress and success of programs under current or future collaboration and license agreements; the sufficiency of the Company’s\ncash resources to fund its operations and pursue its corporate objectives; and technical and other unexpected hurdles in the development,\nmanufacture and supply of the Company’s product candidates, may delay its timing, change its plans, increase its costs, or otherwise\nnegatively impact its business or the sufficiency of its cash resources to fund operations.\n\n \n\nThese risks and uncertainties are described in the Company’s\nmost recent Annual Report on Form 10-K filed with the Securities and Exchange Commission as updated by its subsequent filings with\nthe Securities and Exchange Commission. All information in this Form 8-K is as of today’s date, and any forward-looking statement\nspeaks only as of the date on which it was made. The Company undertakes no obligation to publicly update or revise this information or\nany forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.\n\n \n\n2\n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: June 1, 2026\n**VOYAGER****THERAPEUTICS, INC.**\n\n \n \n\n \nBy:\n*/s/ Alfred Sandrock, M.D., Ph.D.*\n\n \n \nAlfred Sandrock, M.D., Ph.D.\n\n \n \n\nChief Executive Officer, President, and Director\n\n*(Principal Executive Officer)*\n\n \n\n3"}